- Home
- SEED vs CLDI Comparison
SEED vs CLDI Comparison
Compare SEED & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEED | CLDI |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 8.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SEED | CLDI |
|---|---|---|
| Price | $1.32 | $1.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.0K | ★ 81.6K |
| Earning Date | 02-09-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,910,081.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.74 | $1.03 |
| 52 Week High | $2.70 | $19.20 |
Technical Indicators
Market Signals| Indicator | SEED | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | 55.52 | 29.92 |
| Support Level | $1.12 | $1.05 |
| Resistance Level | $1.20 | $1.16 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 85.19 | 13.04 |
Price Performance
Historical ComparisonAbout SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.